| Annual · values | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.14% | 41.99% | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -8498.85% | -26267.67% | — | — | -42778.38% | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | -42778.38% | — | — | — | — | — | — | — |
| Net Margin | -8513.44% | -28127.25% | — | — | -45528.64% | — | — | — | — | — | — | — |
| Current Ratio | 0.80 | 0.15 | 0.94 | 3.04 | 0.01 | 0.04 | 0.02 | 0.07 | 0.05 | 0.01 | 0.01 | 0.06 |
| Quick Ratio | 0.80 | 0.15 | 0.94 | 3.04 | 0.01 | 0.04 | 0.02 | 0.07 | 0.05 | 0.01 | 0.01 | 0.06 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | 2599.52% | 352.57% | 82331.89% | -151.66% | 80.51% | 138.04% | 65.68% | 61.57% | 44.49% | 60.96% | -10.69% | 105.23% |
| ROA | -814.60% | -1399.49% | -411.93% | -101.93% | -4135.60% | -3115.97% | -3556.54% | -3021.08% | -821.88% | -7965.23% | 668.40% | -464.31% |
| Asset Turnover | 0.10 | 0.05 | 0.00 | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value / Share | -0.16 | -1.31 | -0.01 | 0.64 | -0.03 | -0.03 | -0.14 | -0.12 | -0.10 | -0.07 | -0.03 | -0.09 |
Zivo Bioscience Inc. is a research and development company specializing in biotechnology, with a focus on leveraging proprietary algal and bacterial strains to create innovative nutritional compounds and bioactive molecules. The company's core operations center around the study, development, and commercialization of naturally derived ingredients targeting both human and animal health. Zivo Bioscience actively develops and licenses intellectual property, including unique algae cultures, extracts, and patented or patent-pending product concepts. Its primary fields of application include human dietary supplements, nutraceuticals, food ingredients, and animal feed additives, with projects addressing areas such as poultry gut health, bovine mastitis, canine joint health, and human immune modulation. Operating across both the biotech and agtech sectors, Zivo’s business model is heavily based on licensing its technology and selling specialized bioactive compounds to manufacturers in the nutrition, supplement, and medical food industries, emphasizing the growing market demand for natural, functional ingredients.